Back to results
US 2014/0228341 A1Published application
Azetidine derivatives as sphingosine 1-phosphate (s1p) receptor modulators
AssigneeAllergan, Inc.
InventorsWenkui K. Fang, Ken Chow, Evelyn G. Corpuz
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel azetidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
Claims15
A compound represented by Formula I, its enantiomers, diastereoisomers, tautomers or a pharmaceutically acceptable salt thereof,
- wherein:
- A is optionally substituted C6-10 aryl, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl or optionally substituted C3-8 cycloalkenyl;
- B is optionally substituted C6-10 aryl, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl or optionally substituted C3-8 cycloalkenyl;
- R1 is H, halogen, —OC1-8 alkyl, optionally substituted C1-8 alkyl, CN, C(O)R11, NR12R13 or hydroxyl;
- R2 is H, halogen, —OC1-8 alkyl, optionally substituted C1-8 alkyl, CN, C(O)R11, NR12R13 or hydroxyl;
- R3 is H, halogen, —OC1-8 alkyl, optionally substituted C1-8 alkyl, CN, C(O)R11, NR12R13 or hydroxyl;
- R4 is H, halogen, —OC1-8 alkyl, optionally substituted C1-8 alkyl, CN, C(O)R11, NR12R13 or hydroxyl;
- R5 is H, halogen, —OC1-8 alkyl, optionally substituted C1-8 alkyl, CN, C(O)R11, NR12R13 or hydroxyl;
- R6 is H, halogen, —OC1-8 alkyl, optionally substituted C1-8 alkyl, CN, C(O)R11, NR12R13 or hydroxyl;
- R7 is H, halogen, —OC1-8 alkyl, optionally substituted C1-8 alkyl, CN, C(O)R11, optionally substituted C6-10 aryl, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, NR12R13 or hydroxyl;
- R8 is H, halogen, —OC1-8 alkyl, optionally substituted C1-8 alkyl, CN, C(O)R11, optionally substituted C6-10 aryl, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, NR12R13 or hydroxyl;
- R9 is H, halogen, —OC1-8 alkyl, optionally substituted C1-8 alkyl, CN, C(O)R11, optionally substituted C6-10 aryl, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, NR12R13 or hydroxyl;
- R10 is H, halogen, —OC1-8 alkyl, optionally substituted C1-8 alkyl, CN, C(O)R11, optionally substituted C6-10 aryl, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, NR12R13 or hydroxyl;
- L1 is O, S, NH or CHR12;
- L2 is O, S or CHR12;
- X is S(O), S or S(O)2;
- R11 is H, OH or C1-8 alkyl;
- a is 1, 2, 3, 4, 5 or 6;
- R12 is H or C1-8 alkyl;
- R13 is H or C1-8 alkyl.
17 more elements
A method of treating a disorder associated with sphingosine-1-phosphate receptor modulation, which comprises administering to a mammal in need thereof, a pharmaceutical composition comprising a therapeutically effective amount of at least one compound of Formula I
- wherein:
- A is optionally substituted C6-10 aryl, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl or optionally substituted C3-8 cycloalkenyl;
- B is optionally substituted C6-10 aryl, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl or optionally substituted C3-8 cycloalkenyl;
- R1 is H, halogen, —OC1-8 alkyl, optionally substituted C1-8 alkyl, CN, C(O)R11, NR12R13 or hydroxyl;
- R2 is H, halogen, —OC1-8 alkyl, optionally substituted C1-8 alkyl, CN, C(O)R11, NR12R13 or hydroxyl;
- R3 is H, halogen, —OC1-8 alkyl, optionally substituted C1-8 alkyl, CN, C(O)R11, NR12R13 or hydroxyl;
- R4 is H, halogen, —OC1-8 alkyl, optionally substituted C1-8 alkyl, CN, C(O)R11, NR12R13 or hydroxyl;
- R5 is H, halogen, —OC1-8 alkyl, optionally substituted C1-8 alkyl, CN, C(O)R11, NR12R13 or hydroxyl;
- R6 is H, halogen, —OC1-8 alkyl, optionally substituted C1-8 alkyl, CN, C(O)R11, NR12R13 or hydroxyl;
- R7 is H, halogen, —OC1-8 alkyl, optionally substituted C1-8 alkyl, CN, C(O)R11, optionally substituted C6-10 aryl, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, NR12R13 or hydroxyl;
- R8 is H, halogen, —OC1-8 alkyl, optionally substituted C1-8 alkyl, CN, C(O)R11, optionally substituted C6-10 aryl, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, NR12R13 or hydroxyl;
- R9 is H, halogen, —OC1-8 alkyl, optionally substituted C1-8 alkyl, CN, C(O)R11, optionally substituted C6-10 aryl, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, NR12R13 or hydroxyl;
- R10 is H, halogen, —OC1-8 alkyl, optionally substituted C1-8 alkyl, CN, C(O)R11, optionally substituted C6-10 aryl, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, NR12R13 or hydroxyl;
- L1 is O, S, NH or CHR12;
- L2 is O, S or CHR12;
- X is S(O), S or S(O)2;
- R11 is H, OH or C1-8 alkyl;
- a is 1, 2, 3, 4, 5 or 6;
- R12 is H or C1-8 alkyl;
- R13 is H or C1-8 alkyl.
17 more elements
Dependencies are inferred from the claim text.